|REVERSIBLY INTERACTS WITH THE P2Y12 RECEPTOR||YES||NO||NO|
|ACTIVE WITHOUT METABOLISM||YES||NO||NO|
|METABOLISM INDEPENDENT OF CYP2C19 GENOTYPE||YES||NO||YES|
|PRIMARY CYP ENZYME FOR METABOLISM||3A4||2C19||3A4 AND 2B6|
BRILINTA is indicated to reduce the rate of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction. For at least the first 12 months following ACS, it is superior to clopidogrel.
BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
In the management of ACS, initiate BRILINTA treatment with a 180-mg loading dose. Administer 90 mg twice daily during the first year after an ACS event. After one year administer 60 mg twice daily. Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg.